NCT07137312 — Mayo Clinic cancer immunotherapy trial
Ex Vivo Expansion (ACT-X)
Registry record
| Registry ID | NCT07137312 ↗ |
|---|---|
| Lead sponsor | Mayo Clinic |
| Collaborators | — |
| Phase | — |
| Status | Recruiting |
| Indication | Solid Tumor, Healthy, Malignant Solid Neoplasm |
| Enrollment | 24 participants (target) |
| Start date | 2025-12-16 |
| Primary completion | 2028-10-31 (est.) |
| Last registry update | 9 Jun 2026 |
Every field above is mirrored from the study record on ClinicalTrials.gov (NCT07137312), which the sponsor maintains and which carries the full protocol summary, eligibility criteria, sites and contacts. No neoantigen vaccine is approved anywhere yet — every program here is investigational, and inclusion is not an endorsement. See the methodology for how the tracker is built.
Where this fits
No modality, tumor or player hub covers this study yet. Browse the field map for the axes the daily brief does track.
Related trials
FAQ
What phase is NCT07137312?
NCT07137312 (Ex Vivo Expansion (ACT-X)) is registered on ClinicalTrials.gov as having no assigned phase, sponsored by Mayo Clinic.
Is NCT07137312 recruiting?
As of the 2026-06-09 registry update, NCT07137312 is listed as "Recruiting". Eligibility criteria, study sites and contacts are maintained by the sponsor on the ClinicalTrials.gov record.
Who is running NCT07137312?
The lead sponsor is Mayo Clinic.
What condition does NCT07137312 study?
The registered conditions are Solid Tumor, Healthy, Malignant Solid Neoplasm. Primary completion is listed as 2028-10-31 (estimated).
Are results available for NCT07137312?
neoag.ai mirrors the registry's factual fields — sponsor, phase, status and dates — and does not publish trial results. Any posted results, publications, or outcome measures appear on the ClinicalTrials.gov record for NCT07137312.
Back to the full neoantigen vaccine trial tracker — 107 studies, refreshed daily from ClinicalTrials.gov. Background: primer, glossary, and the companies landscape.